Should I buy or sell HLS Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares. View HLS analyst ratings or view top-rated stocks .

What is HLS Therapeutics' stock price target for 2024?

4 analysts have issued 12 month price targets for HLS Therapeutics' shares. Their HLS share price targets range from C$4.15 to C$5.00. On average, they expect the company's stock price to reach C$4.58 in the next twelve months. This suggests that the stock has a possible downside of 6.4%. View analysts price targets for HLS or view top-rated stocks among Wall Street analysts .

How have HLS shares performed in 2024?

HLS Therapeutics' stock was trading at C$3.95 at the beginning of 2024. Since then, HLS stock has increased by 23.8% and is now trading at C$4.89. View the best growth stocks for 2024 here .

When is HLS Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HLS earnings forecast .

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) released its earnings results on Thursday, March, 14th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. The firm earned $21.60 million during the quarter, compared to analyst estimates of $21.83 million. HLS Therapeutics had a negative net margin of 43.65% and a negative trailing twelve-month return on equity of 24.69%.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics declared a quarterly dividend on Thursday, April 27th. Investors of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date is Thursday, April 27th. Read our dividend analysis for HLS .

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 5.52%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for HLS .

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT) , Fairfax Financial (FFH) , Fortis (FTS) , Aurora Cannabis (ACB) , Aphria (APHA) , Alimentation Couche-Tard (ATD.B) , BlackBerry (BB) , BCE (BCE) , Bank of Montreal (BMO) and Bank of Nova Scotia (BNS) .

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:HLS

HLS Therapeutics (HLS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free HLS Stock Alerts

C$4.89

-0.05 (-1.01%)

(As of 04/16/2024 ET)

Compare

Today's Range: C$4.89
▼
C$5.01
50-Day Range: C$3.61
▼
C$5.17
52-Week Range: C$3.34
▼
C$7.12

Volume: 5,800 shs
Average Volume: 10,113 shs
Market Capitalization: C$156.09 million

P/E Ratio: N/A
Dividend Yield: 4.09%
Price Target: C$4.58

Stock Analysis Analyst Forecasts Chart Competitors Dividend Earnings Headlines Insider Trades

Get HLS Therapeutics alerts:

HLS Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 6.4% Downside
C$4.58 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.07 out of 5 stars

1.1

Analyst's Opinion

Consensus Rating
HLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
HLS Therapeutics has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for HLS.

1.7

Dividend Strength

Dividend Leadership
HLS Therapeutics is a leading dividend payer. It pays a dividend yield of 5.52%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
HLS Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HLS.

0.9

News and Social Media Coverage

News Sentiment
HLS Therapeutics has a news sentiment score of -1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
MarketBeat Follows
2 people have added HLS Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HLS Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.49% of the stock of HLS Therapeutics is held by insiders.
Percentage Held by Institutions
59.62% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of HLS Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of HLS Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
HLS Therapeutics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About HLS Therapeutics Stock (TSE:HLS)

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLS Stock News Headlines

April 9, 2024 | finance.yahoo.com

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 9, 2024 | americanbankingnews.com

HLS Therapeutics (TSE:HLS) Shares Up 9.8%

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 8, 2024 | finance.yahoo.com

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

March 17, 2024 | finance.yahoo.com

Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57

March 14, 2024 | finance.yahoo.com

HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%

March 14, 2024 | finance.yahoo.com

HLS Therapeutics Announces Fiscal 2023 Financial Results

March 13, 2024 | markets.businessinsider.com

HLS Therapeutics earnings: here's what to expect

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 21, 2024 | finance.yahoo.com

Several Insiders Invested In HLS Therapeutics Flagging Positive News

February 6, 2024 | ca.finance.yahoo.com

Stocks in play: HLS Therapeutics Inc.

February 6, 2024 | finance.yahoo.com

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

December 20, 2023 | msn.com

Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023

December 18, 2023 | marketwatch.com

HLS Therapeutics CFO Tim Hendrickson to Step Down

December 18, 2023 | msn.com

HLS Therapeutics appoints John Hanna as interim CFO

December 18, 2023 | finance.yahoo.com

HLS Therapeutics Announces CFO Departure

December 11, 2023 | msn.com

2 Top Pharmaceutical Stocks to Buy on the TSX Today

November 15, 2023 | finance.yahoo.com

Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates

November 14, 2023 | finance.yahoo.com

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

November 9, 2023 | marketwatch.com

HLS Therapeutics Plans to Buyback Up to 5% of Its Shares

November 9, 2023 | finance.yahoo.com

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

November 9, 2023 | markets.businessinsider.com

HLS Therapeutics earnings preview: what Wall Street is expecting

October 2, 2023 | finance.yahoo.com

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

September 7, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy HLS Therapeutics Stock

August 26, 2023 | seekingalpha.com

HLTRF HLS Therapeutics Inc.

August 23, 2023 | theglobeandmail.com

HLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)

August 13, 2023 | markets.businessinsider.com

Bloom Burton Remains a Buy on HLS Therapeutics Inc (HLS)

See More Headlines

Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: TSE:HLS
CUSIP: N/A
CIK: N/A
Web: www.hlstherapeutics.com
Phone: 647-495-9000
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$4.58
High Stock Price Target: C$5.00
Low Stock Price Target: C$4.15
Potential Upside/Downside: -6.4%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($1.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-27,530,000.00
Net Margins: -43.65%
Pretax Margin: N/A
Return on Equity: -24.69%
Return on Assets: -2.87%

Debt

Debt-to-Equity Ratio: 89.69
Current Ratio: 1.65
Quick Ratio: 1.01

Sales & Book Value

Annual Sales: C$63.07 million
Price / Sales: 2.47
Cash Flow: C$0.32 per share
Price / Cash Flow: 15.22
Book Value: C$3.06 per share
Price / Book: 1.60

Miscellaneous

Outstanding Shares: 31,920,000
Free Float: N/A
Market Cap: C$156.09 million
Optionable: Not Optionable
Beta: 1.16

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Jason A. Gross Pharm.D. (Age 59)
Vice President of Scientific Affairs
Comp: $354.16k
Mr. Ryan C. Lennox B.A. (Age 43)
J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary
Comp: $389.24k
Mr. Craig Stuart Millian M.B.A. (Age 56)
CEO & Director
Mr. John Hanna CPA
CGA, M.B.A., Interim CFO & Non-Independent Director
Brian T. Walsh
Senior Vice President of Commercial
Mr. David Spence (Age 56)
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

HLS Stock Analysis - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares.
View HLS analyst ratings or view top-rated stocks.
What is HLS Therapeutics' stock price target for 2024?: 4 analysts have issued 12 month price targets for HLS Therapeutics' shares. Their HLS share price targets range from C$4.15 to C$5.00. On average, they expect the company's stock price to reach C$4.58 in the next twelve months. This suggests that the stock has a possible downside of 6.4%.
View analysts price targets for HLS or view top-rated stocks among Wall Street analysts.
How have HLS shares performed in 2024?: HLS Therapeutics' stock was trading at C$3.95 at the beginning of 2024. Since then, HLS stock has increased by 23.8% and is now trading at C$4.89.
View the best growth stocks for 2024 here.
When is HLS Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HLS earnings forecast.
How were HLS Therapeutics' earnings last quarter?: HLS Therapeutics Inc. (TSE:HLS) released its earnings results on Thursday, March, 14th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. The firm earned $21.60 million during the quarter, compared to analyst estimates of $21.83 million. HLS Therapeutics had a negative net margin of 43.65% and a negative trailing twelve-month return on equity of 24.69%.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?: HLS Therapeutics declared a quarterly dividend on Thursday, April 27th. Investors of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date is Thursday, April 27th.
Read our dividend analysis for HLS.
Is HLS Therapeutics a good dividend stock?: HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 5.52%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HLS.
What other stocks do shareholders of HLS Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).
How do I buy shares of HLS Therapeutics?: Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:HLS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

HLS Therapeutics (HLS) Stock Price, News & Analysis

HLS Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

MarketBeat Follows

Company Ownership

Earnings and Valuation

About HLS Therapeutics Stock (TSE:HLS)

HLS Stock Price History

HLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

HLS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™